Mosunetuzumab — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

5 Recruiting

6 Completed trials

7 Sponsors

12 Countries

Phase III

Phase II

Phase I/II

Phase III: 3 Phase II: 4 Phase I/II: 5

Oversight events:

1 serious breach 4 urgent safety measures 4 unexpected events across 6 trials

View oversight register →

Indications tested

Follicular lymphoma 3 Diffuse large B-cell lymphoma recurrent 2 Marginal zone lymphoma refractory 2 Mantle cell lymphoma recurrent 1 Richter's syndrome 1 Follicular lymphoma stage III 1 Waldenstrom´s macroglobulinaemia refractory 1 Follicle centre lymphoma follicular grade I II III recurrent 1 Marginal zone lymphoma recurrent 1 Waldenstrom´s macroglobulinaemia recurrent 1 Follicle centre lymphoma follicular grade I II III 1 Follicular lymphoma stage II 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 5 LYSARC 2 BeOne Medicines AG 1 Fondazione Italiana Linfomi Ets 1 Genentech Inc. 1 Grupo Espanol De Leucemia Linfocitica Cronica 1 Oslo University Hospital HF 1

All trials

12 total

QIMPD SUBMISSION ONLY Not authorised

2023-509510-11-00 Phase III 1 country F. Hoffmann-La Roche AG
A Study to understand the Effectiveness, Safety, and what the body does to Mosunetuzumab in participants with Systemic Lupus Erythematosus w… Recruiting

2024-519930-22-00 Phase II 1 country F. Hoffmann-La Roche AG
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Phase I/II 3 countries BeOne Medicines AG
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Phase III 6 countries Lysarc
CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) Recruiting

2023-505621-13-00 Phase II 1 country Grupo Espanol De Leucemia Linfocitica Cronica
MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting

2022-501810-77-00 Phase III 5 countries Lysarc
Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Ended

2023-506049-52-00 Phase II 1 country Fondazione Italiana Linfomi Ets
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended

2022-500100-21-01 Phase II 4 countries Oslo University Hospital Hf
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i… Ended

2023-507236-20-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined with Atezolizumab in Non-Hodgkin's … Ended

2023-506820-10-00 Phase I/II 2 countries Genentech Inc.
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch… Ended

2023-507498-16-00 Phase I/II 2 countries F. Hoffmann-La Roche AG

Showing 1–12 of 12 trials

← All drugs A–Z